Predictive Role of Ki-67 and Proliferative-Cell Nuclear Antigen (PCNA) in Recurrent Cholesteatoma.
暂无分享,去创建一个
Ö. Yiğit | Y. Çakır | E. Araz Server | H. Demirhan | Ecem Sevim Longur | Sevim Baykal Koca | Çiğdem Kalaycık Ertugay
[1] S. Xie,et al. The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma , 2017, European Archives of Oto-Rhino-Laryngology.
[2] T. Ovesen,et al. Incidence, 10-year recidivism rate and prognostic factors for cholesteatoma , 2017, The Journal of Laryngology & Otology.
[3] K. Sakurai,et al. Cytokeratin 13, Cytokeratin 17, and Ki-67 Expression in Human Acquired Cholesteatoma and Their Correlation With Its Destructive Capacity , 2017, Clinical and experimental otorhinolaryngology.
[4] K. Srinivas,et al. ACQUIRED CHOLESTEATOMA IN CHILDREN AND ADULTS - A CLINICO-PATHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY OF ITS CHARACTERISTICS , 2017 .
[5] S. Xie,et al. Acquired cholesteatoma epithelial hyperproliferation: Roles of cell proliferation signal pathways , 2016, The Laryngoscope.
[6] W. Grolman,et al. The disease recurrence rate after the canal wall up or canal wall down technique in adults , 2016, The Laryngoscope.
[7] E. Özer,et al. Analysis of histopathological aspects and bone destruction characteristics in acquired middle ear cholesteatoma of pediatric and adult patients. , 2016, International journal of pediatric otorhinolaryngology.
[8] Brandon A Mccutcheon,et al. Surgical Technique and Recurrence in Cholesteatoma: A Meta-Analysis , 2013, Audiology and Neurotology.
[9] D. Preciado,et al. The role of inhibitor of DNA‐binding (Id1) in hyperproliferation of keratinocytes: the pathological basis for middle ear cholesteatoma from chronic otitis media , 2010, Cell proliferation.
[10] Jizhen Lin,et al. Identification of Id1 in acquired middle ear cholesteatoma. , 2008, Archives of otolaryngology--head & neck surgery.
[11] L. Chyczewskî,et al. Some markers of proliferative activity in cholesteatoma epithelium in adults. , 2006, Medical science monitor : international medical journal of experimental and clinical research.
[12] S. Schraff,et al. Pediatric Cholesteatoma: A Retrospective Review , 2004 .
[13] A. Desaulty,et al. Aggressiveness and Quantification of Epithelial Proliferation of Middle Ear Cholesteatoma by MIB1 , 2003, The Laryngoscope.
[14] R. Kiss,et al. Detection of Macrophage Migration Inhibitory Factor (MIF) in Human Cholesteatomas and Functional Implications of Correlations to Recurrence Status and to Expression of Matrix Metalloproteinases‐3/9, Retinoic Acid Receptor‐β, and Anti‐apoptotic Galectin‐3 , 2001, The Laryngoscope.
[15] T. Paunesku,et al. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome , 2001, International journal of radiation biology.
[16] R. Kiss,et al. Determination of the Levels of Expression of Sarcolectin and Calcyclin and of the Percentages of Apoptotic But Not Proliferating Cells to Enable Distinction Between Recurrent and Nonrecurrent Cholesteatomas , 1999, The Laryngoscope.
[17] E. Kastenbauer,et al. Epidermal growth factor receptor (EGF-R) in human middle ear cholesteatoma: an analysis of protein production and gene expression. , 1996, The American journal of otology.
[18] M. Paksoy,et al. [Evaluation of Ki-67 expression in recurrent cases of cholesteatoma]. , 2007, Kulak burun bogaz ihtisas dergisi : KBB = Journal of ear, nose, and throat.
[19] Y. Choung,et al. Original contributions Nucleoplasm staining patterns and cell cycle-associated expression of Ki-67 in middle ear cholesteatoma , 2005 .
[20] Y. Hishikawa,et al. Possible Involvement of Keratinocyte Growth Factor and Its Receptor in Enhanced Epithelial-Cell Proliferation and Acquired Recurrence of Middle-Ear Cholesteatoma , 2003, Laboratory Investigation.